Doximity (DOCS) Stock Forecast & Price Target

$52.05 -0.81 (-1.53%)

(As of 11/14/2024 ET)

Doximity - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
0

Hold
10

Buy
7

Based on 17 Wall Street analysts who have issued ratings for Doximity in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 10 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for DOCS.

Consensus Price Target

$50.57
-2.84% Downside

According to the 17 analysts' twelve-month price targets for Doximity, the average price target is $50.57. The highest price target for DOCS is $75.00, while the lowest price target for DOCS is $30.00. The average price target represents a forecasted downside of -2.84% from the current price of $52.05.

DOCS Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	10 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$50.57	$35.83	$30.18	$28.40
Forecasted Upside	-2.84% Downside	-19.19% Downside	-15.58% Downside	11.81% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Election warning coming true… (Ad)

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

DOCS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DOCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Doximity Stock vs. The Competition

Type	Doximity	Medical Companies	S&P 500
Consensus Rating Score	2.47	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-2.82% Downside	19,889.00% Upside	8.58% Upside
News Sentiment Rating	Positive News See Recent DOCS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Truist Financial 2 of 5 stars		Boost Target	Hold ➝ Hold	$35.00 ➝ $49.00	-6.72%
11/14/2024	Morgan Stanley 3 of 5 stars		Upgrade	Underweight ➝ Equal Weight	$33.00 ➝ $53.00	+0.23%
11/13/2024	Canaccord Genuity Group 1 of 5 stars		Reiterated Rating	Buy ➝ Hold	$40.00 ➝ $60.00	+3.32%
11/11/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$52.00 ➝ $75.00	+24.98%
11/8/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $65.00	+11.00%
11/8/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Schoenhaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$70.00	+61.22%
Watch this before it gets removed (Ad) If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now.
11/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Berenshteyn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$19.00 ➝ $41.00	-5.57%
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$34.00 ➝ $45.00	+0.74%
10/7/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$32.00 ➝ $45.00	+2.67%
9/17/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Kesavabhotla Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/17/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$41.00 ➝ $45.00	+14.10%
8/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$27.00 ➝ $30.00	-16.11%
8/9/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Berg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$38.00	+48.03%
5/17/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$32.00	+13.11%
11/10/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$21.00 ➝ $23.00	-3.48%
8/9/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:00 AM ET.

DOCS Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Doximity is $50.57, with a high forecast of $75.00 and a low forecast of $30.00.
: 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last twelve months. There are currently 10 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares.
: According to analysts, Doximity's stock has a predicted downside of -2.84% based on their 12-month stock forecasts.
: Over the previous 90 days, Doximity's stock had 5 upgrades and 1 downgrade by analysts.
: Doximity has been rated by research analysts at Baird R W, Bank of America, Barclays, Canaccord Genuity Group, Canaccord Genuity Group, Evercore ISI, JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Raymond James, Robert W. Baird, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Doximity less than other "medical" companies. The consensus rating for Doximity is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DOCS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Election warning coming true… (Ad)

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

This page (NASDAQ:DOCS) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Doximity (DOCS) Stock Forecast & Price Target